Greatness and disillusionment of U.S Biotech : the Vertex Case

This article (in French) explores the ups and downs of Vertex Pharmaceuricals, a promising biotech expected last year to turn a larger pharma after series of positive results regarding its treatment Telaprevir against Hepatitis C. Vertex Pharmaceuticals is now facing tough and unexpected competition from Pharmasset, a small New-Jersey based company, recently aquired by Gileat for $ 11.5 Billions. The firm may have developed a larger product (i.e targetting a larger market) than Telaprevir. Needless to say this is a dire straight for Vertex..

To read the whole story, please click here !


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s